IRD logo

Opus Genetics, Inc.

IRD
Healthcare|Biotechnology|US
$4.18
+0.17 (+4.37%)
Cash / Share
$0.93
Next Earnings Report
Nov 11, 2026
EPS est. -$0.14 · Revenue est. $1.5M
Financing Filings (last 12 months)
5
Shelf registrations / offering prospectuses — latest Aug 7, 2026 (S-3). Possible dilution.

Upcoming Data Readouts (4)

Aug 2027
Est. completion
P3Vision Loss Night
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
NCT07140783n=580
Jun 2028
Est. completion
P1P2LCA5
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
NCT05616793n=22
Aug 2030
Est. completion
P1P2ARB
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
NCT07185256n=10
Dec 2032
Est. completion
P1P2Leber Congenital Amaurosis
Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)
NCT07681778n=10

Recent Press Releases

Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
Nov 5, 2026 · GlobeNewsWire
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
Nov 3, 2026 · GlobeNewsWire
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 2, 2026 · GlobeNewsWire
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
Oct 29, 2026 · GlobeNewsWire
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood Blindness
Oct 21, 2026 · GlobeNewsWire
Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Oct 16, 2026 · GlobeNewsWire
Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026
Oct 15, 2026 · GlobeNewsWire
Opus Genetics to Present at the Chardan Annual Healthcare Conference
Oct 13, 2026 · GlobeNewsWire
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
Sep 9, 2026 · GlobeNewsWire
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Sep 2, 2026 · GlobeNewsWire

SEC Filings (113)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Oct 21, 20268-KMaterial eventDocumentIndex
Oct 15, 20268-KMaterial eventDocumentIndex
Sep 11, 20268-KMaterial eventDocumentIndex
Sep 9, 20268-KMaterial eventDocumentIndex
Aug 14, 2026EFFECTDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 7, 2026S-3Shelf registrationDocumentIndex
Aug 6, 202610-QQuarterly reportDocumentIndex
Aug 6, 20268-KMaterial eventDocumentIndex
Jun 17, 2026424B2Offering prospectusDocumentIndex
Jun 16, 20268-KMaterial eventDocumentIndex
Jun 16, 20268-KMaterial eventDocumentIndex
Jun 15, 2026EFFECTDocumentIndex
Jun 5, 2026S-3Shelf registrationDocumentIndex
May 20, 2026SC 13D/AActivist / 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 15, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 15, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 14, 2026S-8Employee stock planDocumentIndex
May 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
May 13, 2026SC 13GPassive 5%+ stakeDocumentIndex
May 12, 202610-QQuarterly reportDocumentIndex
May 12, 20268-KMaterial eventDocumentIndex
Apr 24, 20268-KMaterial eventDocumentIndex
Apr 22, 2026EFFECTDocumentIndex
Apr 22, 20268-KMaterial eventDocumentIndex
Apr 21, 2026S-3/AShelf registrationDocumentIndex
Apr 7, 20268-KMaterial eventDocumentIndex
Apr 7, 20268-KMaterial eventDocumentIndex
Mar 23, 2026ARSAnnual report to holdersDocumentIndex
Mar 23, 2026DEF 14AProxy / shareholder voteDocumentIndex
Mar 13, 2026S-3Shelf registrationDocumentIndex
Mar 12, 2026PRE 14AProxy / shareholder voteDocumentIndex
Mar 12, 202610-KAnnual reportDocumentIndex
Mar 10, 20268-KMaterial eventDocumentIndex
Feb 19, 20268-KMaterial eventDocumentIndex